Ligand Pharmaceuticals Incorporated Sustainability Profile
Ligand Pharmaceuticals Incorporated, commonly referred to as Ligand, is a prominent biopharmaceutical company headquartered in the United States. Founded in 1992, Ligand has established itself as a leader in the life sciences industry, focusing on the development of innovative therapies and drug discovery solutions. The company operates primarily in the United States, with significant influence in global markets. Ligand's core business areas include the development of proprietary drug candidates and the licensing of its extensive portfolio of drug discovery technologies. Notable products such as the Captisol® technology, which enhances the solubility and stability of pharmaceutical compounds, set Ligand apart in the competitive landscape. With a strong market position, Ligand has achieved numerous milestones, including strategic partnerships with major pharmaceutical companies, solidifying its reputation as a key player in advancing healthcare solutions.
DitchCarbon Score
How does Ligand Pharmaceuticals Incorporated's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ligand Pharmaceuticals Incorporated's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ligand Pharmaceuticals Incorporated's reported carbon emissions
Ligand Pharmaceuticals Incorporated, headquartered in the US, currently does not have available carbon emissions data for the most recent year. As a result, there are no specific figures regarding their Scope 1, Scope 2, or Scope 3 emissions. Additionally, the company has not outlined any formal reduction targets or commitments to climate initiatives, such as those from the Science Based Targets initiative (SBTi) or other industry standards. Without emissions data or reduction initiatives, it is unclear how Ligand Pharmaceuticals is addressing climate change within its operations. The absence of reported emissions and commitments may reflect a broader trend in the industry, where many companies are still developing their sustainability strategies.
How Carbon Intensive is Ligand Pharmaceuticals Incorporated's Industry?
How Carbon Intensive is Ligand Pharmaceuticals Incorporated's Location?
Ligand Pharmaceuticals Incorporated's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ligand Pharmaceuticals Incorporated has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.